A corporate venture arm of a large pharmaceutical company manages an evergreen fund and currently holds $750 million in assets under management. The fund invests separately from the corporate and is not mandated to invest in areas of strategic relevance with the corporate. The firm makes equity investments in early venture rounds. The firm typically invests up to $10M initially with a total of $15-25M going to a single company over multiple financing rounds. The firm is willing to both lead and co-invest in companies located around the globe and could make as many as 5-6 investments over the next year.

The firm invests in therapeutics, medical devices, and healthcare IT. The firm invests in early stages of development, from preclinical up to Phase IIa drug trials for therapeutics; and for medical devices the firm prefers to invest in companies that are anywhere from just starting a PMA study to on the market. The firm is interested in all classes and indications of therapeutics and devices with their main focus being that the technology be truly innovative and novel. They are not interested in cases of reformulations, re-purposing or “me too” ideas. The firm makes approximately 75% of its investment in therapeutics and 25% across medical devices, and healthcare IT although they are actively looking to increase exposure in these areas. The firm is also open to investing in laboratory equipment and drug development enabling technologies though this area is less of a focus.

The firm prefers to invest in management teams that have demonstrated prior success in the life science industry and are oriented on the goal of bringing a product to market. The firm is currently most interested in privately held companies and looks to take a board seat following investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based venture capital investment firm with an additional office in the USA is investing from its US $200M fund with a focus on high-tech enterprises in China and western countries. The company seeks to invest in innovative enterprises in sectors including: biomedicine, medical devices, healthcare and bio-tech. Typical equity investments range from $1-6 million in Angel, Series A and B rounds. The firm is looking for opportunities in China, the US and Canada.

Within healthcare, the firm considers biomedicine, medical devices, and healthcare IT. The firm is most interested in personalized medicine products with an angle to the China market. Within healthcare IT, the firm prefers home-care, consumer, or physician-patient interface products. The firm considers products from Angel Round to Series B.

The firm is looking for competent management teams. The firm may request distribution rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life-sciences focused venture capital firm is currently making investments out of its third fund. The firm primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1M initially and up to $2M over the lifetime of the investment. The firm is focused on companies located in Southern California and the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

The firm is looking for companies in sectors of therapeutics, medical devices, diagnostics, life science tools and healthcare IT. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A USA-based venture capital firm builds and invests in companies in the healthcare sector, with a focus on personalized health and consumer health. The firm typically invests in seed or Series A rounds and initial investments range from $150,000-$1.5 million, with a potential commitment of up to $5 million over the life of the investment. The firm focuses on companies on the US East Coast but can invest across the USA and Canada.

The firm focuses on healthtech and tech-enabled health services. The firm is also open to investing in devices and diagnostics, but only if they are targeted at consumers as users, rather than physicians, and the firm avoids investing in implantable devices and devices that require a PMA. The firm is open to investing in any area of medicine but prefers to invest in technologies related to chronic diseases, including disease management and care engagement tools. The firm has a strong interest in addiction treatments and physiology, and is also interested opportunities in preventative care and wellness. Neurodegenerative diseases and cancer are also of high interest.

The firm generally does not invest in companies that face FDA regulatory risk; the firm invests in companies with products that are already approved or do not require FDA approval. The firm prefers to invest in revenue generating companies but will consider startups that will begin to generate revenue in 6-12 months.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm who has raised over $1.9 billion is currently making investments out of its vintage 2016 $616 million fund. The firm seeks opportunities to transform patient’s lives by working at the intersection of science, medicine, strategy and business. The firm typically makes equity investments in the range of $40-$50 million in the companies it builds. Allocations are allocated in milestone driven tranches as their companies progress to and through clinical trials. The firm is geographically focused with portfolio companies near their offices in Boston and San Francisco.

The firm is currently building companies that will develop therapeutics across a diverse set of modalities: small molecules, biologics, gene therapy, and cell therapy. In terms of indication the firm is most interested in areas of oncology, cardiovascular, neurology, rare diseases, metabolic disorders and immunology. The firm typically builds companies with early discovery stage and pre-clinical assets that are within 3 years to filing an IND. The firm is focused on building product engine companies and typically does not build single asset companies, but will consider business development opportunities around assets relevant to companies it is building.

The firm builds companies with highly experienced management teams and focused recruiting great management teams for its companies. The firm acts as a long term strategic investor and takes a board seat into companies following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A single family office with over 45 years of entrepreneurship experience in the life sciences sector invests broadly in healthcare and is open to companies of all stages. The size of investment can largely vary depending on the stage of the company. The firm has invested mainly in USA-based companies but is open to global opportunities.

The firm has a broad interest in healthcare and is most interested in private biotech companies, with a few investments in medical device companies as well. In therapeutics, the firm’s sweet spot is from pre-clinical to late-stage II, with particular interest in assets with accelerated or de-risked regulatory pathways. The firm is interested in all indications, including oncology and immunotherapies. The firm also considers gene therapy as an area of high interest. In terms of medical devices, the firm is most interested in minimally invasive devices and is open to 510k and PMA regulatory pathways.

The firm seeks to work with experienced management teams with strong scientific expertise. Another important consideration is other investors that have participated in the financing. The firm invests in both public and private companies and will most likely seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com